REAL-Time Continuous Glucose Monitoring: A New Gold Standard
TORONTO, Oct. 30 /CNW/ - As Diabetes Awareness Month (November)
approaches, Medtronic is pleased to launch its latest technological
advancement in the field of diabetes management - the Guardian(R) REAL-Time
Continuous Glucose Monitoring System.
Monitoring blood glucose (sugar) levels throughout the day (continuous
glucose monitoring) and intervening early to reduce the frequency and severity
of high or low blood glucose levels is key to effective management of type 1
The Guardian(R) REAL-Time System is the first of its kind in Canada to
offer the benefits of advanced REAL-Time Continuous Glucose Monitoring to any
patient with diabetes. The System displays blood glucose readings every five
minutes, and alerts the patient when blood glucose levels reach preset high or
low limits. The device also offers special software designed to download
glucose data to a computer where graphs can be displayed and interpreted
independently or in consultation with one's diabetes care team. The system was
recently made available in Canada.
"The comprehensive information made available using the Guardian(R)
REAL-Time is extremely valuable for assessing how well an individual with
diabetes is managing," said Dr. Amir Hanna, MB, BCh, FRCPC, Professor
Emeritus, Department of Medicine, University of Toronto. "In fact, the system
enables people with diabetes to take immediate action to improve their blood
glucose control and subsequently reduce the associated risk of complications."
This Guardian(R) REAL-Time Continuous Glucose Monitor enables patients to
discover how diet, exercise, medication and lifestyle affect their blood
glucose control, and track how fast - and in what direction - their blood
glucose levels are heading. Real-time readings allow patients to intervene
earlier to reduce the frequency and severity of high and low blood glucose
Supported by data, this technology is rapidly becoming a new gold
standard in the treatment of diabetes. Patients who monitored their glucose
levels continuously using the Guardian(R) REAL-Time System experienced a one
percentage point reduction in A1c levels(1) - a measurable decrease associated
with a 35 per cent reduction in diabetes related complications(2). Further,
the presence of real-time alerts reduced the duration of low blood glucose
excursions by an average of 28 minutes per event(3) - and the less time an
individual spends in a low or high blood glucose situation, the better overall
control they have.
More About Continuous Glucose Monitoring
Today's standards for assessing blood glucose control include A1c tests
and fingerstick measurements, yet both have limitations. An A1c measurement
reflects a patient's average blood glucose control over a three-month period.
It does not reveal the day-to-day glucose fluctuations that can contribute to
diabetes-related complications. Fingerstick measurements only reveal a glucose
value at a single moment in time.
(1) Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in
poorly controlled patients with type 1 diabetes using real-time
continuous glucose monitoring. Diabetes Care 2006; 29:2730-2732.
(2) Epidemiology of Diabetes Interventions and Complications. NEJM.
Dec 22, 2005: Vol. 353 No.25.
(3) Bode B, Gross K, Rikalo N, et al. Alarms based on real-time sensor
glucose values alert patients to hypo- and hyperglycemia: the
guardian continuous monitoring system. Diabetes Technol Ther 2004;6:
In contrast, real-time continuous blood glucose monitoring allows
patients to view glucose trends throughout the day and night and anticipate
how they might manage their diabetes.
Integrating Continuous Glucose Monitoring with the Insulin Pump
In addition to the newly launched Guardian(R) REAL-Time, Medtronic
Diabetes is pleased to offer people with diabetes the MiniMed Paradigm(R)
REAL-Time System. Launched in 2006, this System integrates continuous glucose
monitoring capabilities with an insulin pump - a world's first and a major
step towards Medtronic's goal of developing an artificial pancreas.
The artificial pancreas - also termed the closed-loop system - is an
external or implantable insulin sensor and pump that continuously monitors
blood glucose levels and automatically delivers insulin depending on the level
and the rate of change in blood glucose.
Diabetes is reaching epidemic proportions. According to the Canadian
Diabetes Association, more than two million Canadians have diabetes and, by
the end of the decade, this number is expected to rise to three million.
Approximately 10 per cent of people with diabetes have type 1 diabetes - their
pancreas does not produce any insulin. The remaining 90 per cent have type 2
diabetes, in which the pancreas does not produce enough insulin or the body
does not effectively use the insulin that is produced.
If left untreated, long term complications of diabetes can lead to heart
failure, blindness, impotence, kidney failure, amputation and in many cases
death. For this reason, it is critical for people with diabetes to
continuously monitor their blood glucose levels and to maintain them in a
About Medtronic Diabetes
Medtronic diabetes (www.medtronic-diabetes.com) is the world leader in
diabetes management. The company's products include insulin pump therapy,
continuous glucose monitoring systems, related disposable products and
diabetes management software.
Medtronic, Inc. (NYSE: MDT) (www.medtronic.com), headquartered in
Minneapolis, is the global leader in medical technology, alleviating pain,
restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic's Annual Report on Form 10-K for the year
ended April 28, 2006. Actual results may differ materially from anticipated
For further information:
For further information: Alison Withey, PraxisPR, email@example.com,
(905) 949-8255 ext. 302; Lauren McConnell, PraxisPR, firstname.lastname@example.org, (905)
949-8255 ext. 227